Eurofins signs agreement to acquire Experchem Laboratories, Inc. in Canada
2015年5月7日 - 2:45PM
ビジネスワイヤ(英語)
Regulatory News:
Eurofins (Paris:ERF):
Eurofins Scientific (EUFI.PA), the world leader in food and
pharmaceutical products testing, announces that it has signed an
agreement to acquire Experchem Laboratories, Inc. (Experchem), a
comprehensive analytical testing service provider, with renowned
competence in nutraceuticals testing. The transaction is expected
to close in 30 days subject to customary closing conditions.
Founded in 1981, Experchem employs about 95 staff at its
laboratory in Toronto, and generates revenues in excess of CA$ 10m.
Certified by both Health Canada and the Food and Drug
Administration (FDA) in the US, Experchem provides comprehensive
testing solutions primarily to pharmaceutical and nutraceutical
industries, with significant expertise in natural health products
(NHPs), the Canadian equivalent of nutraceuticals, as well as in
functional foods and beverages.
The company provides full testing and regulatory services to
ensure that clients’ products are fully compliant with NHP
regulations, and is ideally positioned for growth, given that
functional food and NHP are Canada's fastest growing agriculture
and agri-food sectors1. Furthermore, whilst Canada currently has
more stringent NHP regulations compared to the US2, reports
indicate that the FDA is increasingly likely to strengthen
nutraceuticals regulations3. Experchem’s expertise, together with
Eurofins’ long-established neutracuticals testing competence center
in Petaluma, California, should therefore reinforce Eurofins’
capabilities to benefit from growth in US nutraceuticals testing
from increased regulations, and achieve leadership in this
attractive market.
In addition, Experchem also conducts full cGMP quality control
(QC) testing services for over the counter (OTC) drugs, providing a
platform for Eurofins to extend its current leading pharmaceutical
products testing position into Canada.
Comment from Dr. Gilles Martin, Eurofins CEO: “The
acquisition of Experchem facilitates Eurofins’ expansion into
Canada, as well as reinforces our capabilities in key niche markets
such as nutraceuticals testing, and our leadership in
biopharmaceutical products quality control. In return, we look
forward to providing Experchem access to the full capabilities of
the Eurofins Group and our client relationships to further
strengthen their position in the domestic market.”
For more information about Eurofins, please visit
www.eurofins.com
1
http://www.agr.gc.ca/eng/industry-markets-and-trade/food-regulations/food-policy-and-regulatory-issues/reports-and-resources/opportunities-and-challenges-facing-the-canadian-functional-foods-and-natural-health-products-sector/?id=14102069022992
Nutraceuticals are not required to undergo pre-market approval
process (http://www.fda.gov/Food/DietarySupplements/) whilst NHPs
must have a license before they can be sold in Canada
(http://www.hc-sc.gc.ca/dhp-mps/prodnatur/about-apropos/index-eng.php)3
The state of New York had published a study finding the Dietary
Supplement Health and Education Act insufficient
(https://www.health.ny.gov/regulations/task_force/docs/dietary_supplement_safety.pdf)
Notes for the editor:
Eurofins – a global leader in bio-analysis
Eurofins Scientific is the world leader in food and
pharmaceutical products testing. It is also number one in the world
in the field of environmental laboratory services and one of the
global market leaders in agroscience, genomics, discovery
pharmacology and central laboratory services.
With over 17,000 staff in more than 200 laboratories across 36
countries, Eurofins offers a portfolio of over 130,000 reliable
analytical methods for evaluating the safety, identity,
composition, authenticity, origin and purity of biological
substances and products. The Group provides its customers with
high-quality services, accurate results on time and expert advice
by its highly qualified staff.
Eurofins is committed to pursuing its dynamic growth strategy by
expanding both its technology portfolio and its geographic reach.
Through R&D and acquisitions, the Group draws on the latest
developments in the field of biotechnology and analytical chemistry
to offer its clients unique analytical solutions and the most
comprehensive range of testing methods.
As one of the most innovative and quality oriented international
players in its industry, Eurofins is ideally positioned to support
its clients’ increasingly stringent quality and safety standards
and the expanding demands of regulatory authorities around the
world.
The shares of Eurofins Scientific are listed on the Euronext
Paris Stock Exchange (ISIN FR0000038259, Reuters EUFI.PA, Bloomberg
ERF FP).
Important disclaimer:
This press release contains forward-looking statements and
estimates that involve risks and uncertainties. The forward-looking
statements and estimates contained herein represent the judgement
of Eurofins Scientific’ management as of the date of this release.
These forward-looking statements are not guarantees for future
performance, and the forward-looking events discussed in this
release may not occur. Eurofins Scientific disclaims any intent or
obligation to update any of these forward-looking statements and
estimates. All statements and estimates are made based on the
information available to the Company’s management as of the date of
publication, but no guarantee can be made as to their validity.
Investor RelationsEurofins Scientific Group+32 2 766
1620ir@eurofins.com
Enerplus (NYSE:ERF)
過去 株価チャート
から 6 2024 まで 7 2024
Enerplus (NYSE:ERF)
過去 株価チャート
から 7 2023 まで 7 2024